Objective: The objective of this systematic review and meta-analysis was to evaluate the optimal modality and frequency of surveillance after endovascular aortic repair (EVAR) in adult patients with abdominal aortic aneurysms.
Abdominal aortic aneurysm (AAA) is a relatively common condition that primarily affects older adults. Approximately 15,000 deaths annually in the United States are attributed to AAA. 1 Endovascular aortic repair (EVAR) was first described in 1991 2 and involves the placement of an expandable stent graft within the aorta to treat aortic disease. In 2003, EVAR surpassed open aortic surgery as the most common technique for repair of AAA, 3 and in 2010 it accounted for 78% of all intact AAA repair in the United States. 4 EVAR is associated with a significant reduction in perioperative mortality and morbidity 5 and fewer cardiac, respiratory, and hemorrhagic complications compared with open repair surgery and requires a shorter hospital stay as well. 6 However, significant concerns remain about complications after EVAR, such as persistent aneurysm growth, new aneurysm formation, potential rupture, endoleaks, device migration, graft thrombosis, infection, and systemic complications. Therefore, long-term post-EVAR surveillance may be necessary to detect complications, which may start without symptoms but be lifethreatening and require prompt intervention. Early detection may allow early intervention and prevent aneurysm growth and rupture. The Society for Vascular Surgery has recommended computed tomography (CT) scanning at 1 month and 12 months during the first postoperative year, with an additional CT scan at 6 months if an abnormality is detected at the first month. After the first year, CT scanning was recommended annually, with the alternative option of ultrasound (US) imaging if no abnormality was detected during the first year. radiation exposure, administration of nephrotoxic contrast agents, and significant cost. [11] [12] [13] Duplex ultrasound (DUS) was also suggested as an alternative to CT for post-EVAR follow-up. DUS is less expensive and does not involve ionizing radiation or exposure to contrast material. Studies of DUS with non-nephrotoxic contrast agents can detect post-EVAR endoleaks and have demonstrated promising results. 14 Magnetic resonance imaging (MRI) had been considered for endoleak detection after EVAR and was suggested to have higher sensitivity than CTA for type II endoleaks. 15 However, there is inconsistency in the literature about the effectiveness of surveillance with MRI or contrast-enhanced CT scan. The Society for Vascular Surgery undertook the task of developing clinical practice guidelines for the care of patients with AAA and commissioned this systematic review to aid in developing recommendations about surveillance. The aim of this systematic review and meta-analysis was to evaluate the optimal image modality and frequency of surveillance in adult patients who underwent EVAR for AAA. Database search. A comprehensive search of several databases from each database's inception to May 10, 2016 , was conducted without language restrictions. Databases included Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced librarian with input from the investigators. Controlled vocabulary supplemented with keywords was used to search for comparative studies of frequency and modality of post-EVAR surveillance. The actual strategy is available in the Appendix (online only). We included studies of adults with AAA who underwent surveillance after any EVAR technique (percutaneous, fenestrated, or branched) with any single or combined imaging tests. The outcomes of interest were endoleaks, mortality, limb ischemia, renal complications, late rupture, and aneurysm-related mortality. We excluded case reports, case series, review articles, mixed abdominal and thoracic aortic aneurysm if not reported separately, and all types of thoracoabdominal aortic aneurysm with the exception of type IV, which is limited to the abdomen. Studies were excluded for not reporting the outcomes of interest, reporting outcomes without a clear time frame or at time points different from those specified a priori, or not specifying the surveillance protocol that had been followed.
Study selection. Two independent reviewers screened the titles and abstracts to determine eligibility for inclusion. Full texts were then retrieved and screened independently by pairs of reviewers. Disagreements between the reviewers were resolved by consensus. An online reference management system was used for study selection (DistillerSR; Evidence Partners, Inc, Ottawa, Canada).
Inter-reviewer agreeability (Cohen's k) was calculated to assess agreement between the reviewers. Data extraction. Two independent reviewers extracted data from relevant studies using a web-based predesigned and piloted extraction form. Data on patients' baseline characteristics, surveillance tests, comparison tests, and outcomes were systematically extracted from each report. Disagreements were discussed until a consensus decision was reached.
Risk of bias assessment and quality of evidence. Two reviewers independently assessed the risk of bias in the included studies using a standardized form based on the Newcastle-Ottawa Scale tool. 17 The assessment considered six main domains, including patient selection, comparability between the two study arms, outcomes assessment, length of follow-up of the study, loss to follow-up, and funding source. The quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation approach. Statistical analysis. Existing systematic reviews and meta-analyses were appraised, cross-referenced, and presented narratively. Results from noncomparative studies were summarized as incidence rates (IRs) and 95% confidence intervals. A random-effects meta-analysis was conducted to pool IRs across the studies. We used the I 2 statistic to estimate the percentage of total between-study variation due to heterogeneity rather than chance (ranging from 0%-100%). 20, 21 I 2 values of 25%, 50%, and 75% were considered to be consistent with low, moderate, and high heterogeneity, respectively. Analysis was conducted using Stata 14 software (StataCorp LP, College Station, Tex).
RESULTS

Search results
Initial database search resulted in 1099 citations along with 146 citations identified by hand search. We eventually included 58 studies. Inter-reviewer agreement was good, with an average weighted k of 0.65. The detailed study selection process is described in the Fig. Of the included studies, 10 were comparatives, 42 were noncomparatives, and 6 were systematic reviews and meta-analyses. The majority of studied patients were older men. The majority of aneurysms were intact. The most common aneurysm location was infrarenal, followed by suprarenal, juxtarenal, and aortoiliac. Multiple comorbidities were reported; smoking was the most common. Detailed description of the included studies is summarized in Table I and of the systematic reviews and meta-analyses in Table II .
Optimal surveillance intervals
Most studies reported detection rates of patientimportant outcomes at 1, 6, 12, 24, 36, 48, and 60 months. There were no studies that compared different surveillance intervals for these outcomes.
Optimal surveillance method
Systematic reviews and meta-analyses. We include six systematic reviews and meta-analyses. The main results are summarized in Table II . In brief, MRI was more sensitive than CTA for endoleak detection, especially for type II endoleak (moderate-quality evidence). 15 Doppler US did not have sufficient diagnostic accuracy for the detection of all endoleaks in routine clinical practice. The diagnostic accuracy of US improves if type II endoleaks are ignored. 74 Doppler US had lower sensitivity than contrast-enhanced CT but a higher specificity for the detection of endloleaks. 78 Doppler US had poor sensitivity for endoleak detection, whereas contrast-enhanced US had high sensitivity. 75 Contrast-enhanced US was likely to be as sensitive as CTA in detecting endoleaks and had higher sensitivity for delayed type II endoleak. 76 Both Doppler US and contrast-enhanced US were highly specific for type I and type III endoleaks. Sensitivity estimates were likely to be similar but less reliable. 77 The quality of this diagnostic evidence was low to moderate because it was derived from observational studies. Observational studies. Forty-two noncomparative studies and 10 comparative studies provided data that allowed meta-analysis of detection rates and, specifically, the noncomparative IR of outcomes of interest at different time points.
Endoleaks. At 1 month, the highest detection rate (24%) was observed using a combined approach of surveillance with noncontrast-enhanced US, noncontrast-enhanced CT, and CTA. At 6 months, the highest detection rate (25%) was observed using CTA surveillance. A combined approach of DUS, noncontrast-enhanced CT, and MRI was reported as the highest endoleak detection rate at 12, 24, 36, and 48 months by 35%, 46%, 51%, and 92%, respectively. At 60 months, the highest detection rate (91%) was observed using a combined approach of surveillance with DUS, CTA, and MRI ( Supplementary Figs 1-7 , online only). Table III summarizes detection rates at all follow-up intervals.
Other outcomes. IRs of other outcomes (mortality, limb ischemia, renal complications, late rupture, and aneurysm-related mortality) in patients who underwent surveillance at different time points using different imaging tests are reported in Supplementary Table I (online  only) . IRs of complications were heterogeneous and overall high. Mortality ranged from 0% to 4% at 1 month and from 2% to 36% at 1 year. Aneurysm-related mortality ranged from 0% to 2% at 1 month and from 1% to 17% at 1 year. Limb ischemia ranged from 3% to 5% at 1 month and from 2% to 8% at 1 year. Renal complications were common only at early time periods (2%-17% at 1 month). Late rupture was rare at all time points (2% or less). Data were insufficient to provide comparative inferences about the best strategy to reduce the risk of such outcomes.
Risk of bias assessment. Supplementary Table II (online only) summarizes risk of bias domains and the overall quality of each study. The overall risk of bias of the included studies was medium to high. Most had adequate cohort selection (representing most of the institutional experience) and most had adequate outcome assessment. However, the majority of the studies (81%) were noncomparative.
DISCUSSION
Main findings. We conducted a systematic review and meta-analysis evaluating surveillance outcomes after EVAR for AAA. MRI had a higher detection rate of endoleaks than CTA, which may suggest better sensitivity (although the incremental detection could represent false-positive findings or lesions that are not clinically important). Doppler US did not have sufficient diagnostic accuracy, whereas contrast-enhanced US was likely to be as sensitive as CTA. The highest endoleak detection rates were in surveillance approaches that used combined tests. We also demonstrated that complication rates were common after EVAR, particularly in the first year, which can serve as a rationale for surveillance. There were no studies that compared different surveillance intervals to determine optimal intervals, with most studies reporting detection rates of patient-important outcomes at 1, 6, 12, 24, 36, 48, and 60 months. The risk of late rupture and aneurysm-related mortality was low after EVAR, which is another important finding, considering that these are the very same outcomes for which patients undergo this procedure. Data were insufficient to provide comparative inferences about the best strategy to reduce the risk of patient-important outcomes, such as mortality, limb ischemia, rupture, and renal complications.
Our study supported the current evidence 65, 68, 78 regarding the superiority of contrast-enhanced CT over Doppler US in terms of sensitivity for endoleak detection at different time points. Similarly, Habets et al 15 concluded that MRI was more sensitive than CTA, especially for type II endoleak, and Haulon et al 61 showed
that MRI after injection of gadolinium was more sensitive than contrast-enhanced CT at 1 month and 6 months.
Practical implications. For surveillance to be justified, a surveillance test with adequate diagnostic accuracy needs to be available, the yield of surveillance needs to be consistent with important prevalent findings, and an effective intervention needs to be available to treat conditions identified by surveillance. In the case of post-EVAR surveillance, these characteristics hold true. In terms of the availability of accurate surveillance tests, this review demonstrated that MRI, CTA, contrast-enhanced CT, color DUS, contrast-enhanced color DUS, three-dimensional contrast-enhanced US, and Doppler US are all tests with reasonable diagnostic accuracy. For example, a higher detection rate by CTA compared with Doppler US does not necessarily imply that CTA should be the preferred strategy all the time. Doppler US is operator dependent, and when it is performed by technologists with adequate training, it can be an appropriate surveillance strategy with good safety, no radiation exposure, and important cost savings. 73 Findings missed by some of the less sensitive tests are likely to be of lesser clinical significance. In terms of the yield of surveillance, this review demonstrated that the risk of endoleak, mortality, limb ischemia, rupture, and renal complications was high and persisted for several years after EVAR. Interventions for treating endoleaks are also available, making the case for surveillance after EVAR. The frequency of surveillance and a pragmatic approach for managing surveillance are less informed by comparative evidence and require reliance on surgical expertise, availability of radiology equipment and expertise, and engagement of patients in shared decision-making. Such recommendations will be provided in a forthcoming guideline from the Society for Vascular Surgery that will use this evidence synthesis summary and provide specific recommendations.
CONCLUSIONS
Several tests with reasonable diagnostic accuracy are available for surveillance after EVAR. The available evidence confirms a high complication rate, particularly in the first year after EVAR, and provides a rationale for surveillance. 10 (("electron beam" adj2 tomograph*) or (comput* adj2 tomograph*) or "cat scan*" or "cine-ct" or "ct scan*" or "ct x-ray*" or CTA or tomodensitometr* or "x ray ct").mp. 18 ((mr adj tomograph*) or (nmr adj tomograph*) or "chemical shift imaging*" or fmri or fmris or "magnetic resonance imaging*" or "magnetization transfer imaging*" or "mr imaging*" or mri or mris or nmr or nmrs or "proton spin tomograph*" or zeugmatograph*).mp.
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19 ((mr adj tomograph*) or (nmr adj tomograph*) or "chemical shift imaging*" or fmri or fmris or "magnetic resonance angiograph*" or "magnetic resonance imaging*" or "magnetization transfer imaging*" or "mr angiograph*" or "mr imaging*" or mri or mris or nmr or nmrs or "proton spin tomograph*" or zeugmatograph*).mp. based) or (meta adj analys*) or (systematic* adj3 review*) or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") adj3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "concurrent study" or "concurrent survey" or "concurrent analysis" or "clinical study" or "clinical trial" or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multi-center study" or "odds ratio" or "confidence interval" or "change analysis").mp,pt. OR CTA OR echogram* OR echograph* OR echoscop* OR echosound OR echotomograph* OR fmri OR fmris OR "magnetic resonance angiograph*" OR "magnetic resonance imaging*" OR "magnetization transfer imaging*" OR "mr angiograph*" OR "mr imaging*" OR mri OR mris OR nmr OR nmrs OR "proton spin tomograph*" OR sonogram* OR sonograph* OR Surveillance OR tomodensitometr* OR ultrasonic OR ultrasonograph* OR ultrasound OR "x ray ct" OR zeugmatograph*) 3 TITLE-ABS-KEY(surveillance) OR TITLE("follow-up") 4 TITLE-ABS-KEY((evidence W/1 based) OR (meta W/1 analys*) OR (systematic* W/3 review*) OR multivariate OR "comparative study" OR "comparative survey" OR "comparative analysis" OR (intervention* W/2 study) OR (intervention* W/2 trial) OR "cross-sectional study" OR "crosssectional analysis" OR "cross-sectional survey" OR "cross-sectional design" OR "prevalence study" OR "prevalence analysis" OR "prevalence survey" OR "disease frequency study" OR "disease frequency analysis" OR "disease frequency survey" OR crossover OR "cross-over" OR cohort* OR "longitudinal study" OR "longitudinal survey" OR "longitudinal analysis" OR "longitudinal evaluation" OR longitudinal* OR ((retrospective OR "ex post facto") W/3 (study OR survey OR analysis OR design)) OR retrospectiv* OR "prospective study" OR "prospective survey" OR "prospective analysis" OR prospectiv* OR "concurrent study" OR "concurrent survey" OR "concurrent analysis" OR "clinical study" OR "clinical trial" OR "case control study" OR "case base study" OR "case referrent study" OR "case referent study" OR "case referent study" OR "case compeer study" OR "case comparison study" OR "matched case control" OR "multicenter study" OR "multi-center study" OR "odds ratio" OR "confidence interval" OR "change analysis") 5 1 and 2 and 3 and 4 6 TITLE-ABS-KEY(newborn* or neonat* or infant* or toddler* or child* or adolescent* or paediatric* or pediatric* or girl or girls or boy or boys or teen or teens or teenager* or preschooler* or "pre-schooler*" or preteen or preteens or "pre-teen" or "pre-teens" or youth or youths) AND NOT TITLE-ABS-KEY(adult or adults or "middle age" or "middle aged" or elderly or geriatric*) 7 OR PMID(4*) OR PMID(5*) OR PMID(6*) OR PMID(7*) OR PMID(8*) OR PMID(9*) 13 11 and not 12 Supplementary Fig 1 (online only) . Endoleaks at 1 month. CCT, Contrast-enhanced computed tomography; CI, confidence interval; CTA, computed tomography angiography; CUS, contrast-enhanced ultrasound; DUS, duplex ultrasound; ES, effect size; ID, identification; MRI, magnetic resonance imaging; NCCT, noncontrastenhanced computed tomography; NCUS, noncontrast-enhanced ultrasound. Supplementary Fig 8 (online only) . Mortality at 1 month. CCT, Contrast-enhanced computed tomography; CI, confidence interval; CTA, computed tomography angiography; DUS, duplex ultrasound; ES, effect size; ID, identification; NCCT, noncontrast-enhanced computed tomography; NCUS, noncontrast-enhanced ultrasound. 1 
